Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474

Kymera Therapeutics, Inc.

Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.
KT-621 Phase 1 healthy volunteer data expected Q2 2025; Phase 1b AD starts Q2 2025 with data Q4 2025.
KT-295 (TYK2) IND/Phase 1 start Q2 2025; data expected late 2025.
KT-474 (IRAK4) Phase 2b dose-ranging in HS and AD ongoing, completion expected 1H26 and mid-2026.
Novel oral immunology program (first-in-class) to be disclosed 1H2025; clinical testing expected early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.